Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB) is an autosomal-dominant bone dysplasia characterized by metaphyseal flaring of long bones, enlargement of the medial halves of the clavicles, maxillary hypoplasia, variable brachydactyly, and dystrophic teeth. We performed genome-wide SNP genotyping in five affected and four unaffected members of an extended family with MDMHB. Analysis for copy-number variations revealed that a 105 kb duplication within RUNX2 segregated with the MDMHB phenotype in a region with maximum linkage. Real-time PCR for copy-number variation in genomic DNA in eight samples, as well as sequence analysis of fibroblast cDNA from one subject with MDMHB confirmed that affected family members were heterozygous for the presence of an intragenic duplication encompassing exons 3 to 5 of RUNX2. These three exons code for the Q/A domain and the functionally essential DNA-binding runt domain of RUNX2. Transfection studies with murine Runx2 cDNA showed that cellular levels of mutated RUNX2 were markedly higher than those of wild-type RUNX2, suggesting that the RUNX2 duplication found in individuals with MDMHB leads to a gain of function. Until now, only loss-of-function mutations have been detected in RUNX2; the present report associates an apparent gain-of-function alteration of RUNX2 function with a distinct rare disease.
Metaphyseal dysplasia with maxillary hypoplasia and brachydactyly (MDMHB [MIM 156510]) is an autosomaldominant bone dysplasia first described by Halal et al. in 1982 in a French Canadian family from the Gaspésie region in Quebec. 1 Affected family members had metaphyseal flare and thin diaphyseal cortices of long bones, bilateral shortness of middle phalanxes or metacarpals, and maxillary hypoplasia. Other skeletal anomalies included mild short stature, enlargement of the medial halves of the clavicles, wide ischial and pubic bones, mild thickening of frontal and parietal skull bones, platyspondyly, and a general radiographic impression of osteoporosis, even though bone density measurements were not reported. Teeth were yellowish and dystrophic, leading to total dental extraction before the end of the second decade in the majority of affected individuals. No extraskeletal abnormalities were noted. It appears that no further MDMHB cases have been reported since this initial description.
We have identified six individuals from a kindred whose clinical and radiographic phenotype closely resembles that of the subjects described by Halal et al. 1 and who also originate from the Gaspésie region in Quebec (Figure 1 ; Tables S1 and S2 available online). Histomorphometric analysis of transiliac bone biopsy samples (from subjects IV-1, IV-2, and IV-6) showed thin cortices and a low amount of trabecular bone ( Figure 1K ). Mineral apposition rate, a marker of bone formation, was low, suggesting a defect in osteoblast function, whereas osteoclast surface, a marker of bone resorption, was normal ( Figure 1L ). Biochemical parameters of bone and mineral metabolism were mostly within normal limits (Table S3) . Lumbar spine bone mineral density was low (z score < À2) for three subjects but was within normal limits for the others. However, peripheral quantitative computed tomography of the radius showed that cortices were very thin at both the metaphysis and the diaphysis (Table S3) .
To search for the disease-causing mutation in this family, we obtained DNA from five affected and four unaffected family members ( Figure 1A ). With approval from the Institutional Review Board of McGill University, we obtained informed consent; assent was obtained from participants aged less than 18 years. We performed whole-genome SNP genotyping in all nine individuals with the Human Omni2.5-Quad chip (Illumina, San Diego, CA). MERLIN software (version 1.1.2) was used for parametric linkage analysis after pruning for linkage disequilibrium. 2 The maximum achievable LOD score of 2.1 was obtained for regions on chromosomes 6, 11, and 15 (Table S4) . Genomic DNA from subjects IV-1 and IV-5 was captured with the Agilent SureSelect 50 Mb oligonuclotide library (Agilent Technologies Inc., Santa Clara, CA) and was sequenced with 100 paired-end reads on Illumina HiSeq2000. By using a bioinformatics ). Mean (error bars: SE) results for cortical width (Ct.Wi), trabecular bone volume per tissue volume (BV/TV), mineral apposition rate (MAR), and osteoclast-covered surface per bone surface (Oc.S/BS) are shown. pipeline as previously described, 3 we found that the 2 subjects shared 17 previously undescribed variants, none of which were located within any of the linkage regions. The SNP array data were analyzed for copy-number variations (CNV) with PennCNV, IPN, CNVpartition, and QuantiSNP algorithms. These CNV analyses showed that all affected individuals of the pedigree had a 105 kb duplication within the linked region on chromosome 6 (chromosomal location 6p12.3; physical position 6: 45,308,920-45,413,885; hg19) whereas this duplication was absent in all unaffected family members ( Figure S1 ). result in nonsense-mediated decay. We therefore judged it unlikely that the effect of the duplication on SUPT3H is involved in the pathogenesis of MDMHB and did not investigate this gene further. In contrast, RUNX2 codes for a transcription factor that is essential for bone formation. 4 ,5 RUNX2 haploinsufficiency leads to cleidocranial dysplasia (CCD [MIM 119600]). 6, 7 A duplication of exons 3 to 5 is predicted to lead to an in-frame addition to the RUNX2 sequence. We therefore performed further investigations on RUNX2. The duplication was confirmed by real-time PCR in genomic DNA from four affected and four unaffected family members ( Figure 2B ). All affected individuals had three copies for the two locations within the sequence affected by the duplication, but two copies at locations telomeric and centromeric of this region. Unaffected family members had two copies for all four locations. This confirmed the presence of a duplication that stretches from intron 2 to intron 5 of RUNX2 and thus includes exons 3 to 5 of RUNX2. These three exons code for the Q/A domain and the runt domain of RUNX2 ( Figure 2C) . The Q/A domain consists of a stretch of 23 glutamine residues followed by 17 alanine residues. The runt domain is the functionally essential DNA binding domain of RUNX2. 8 The duplication of exons 3 to 5 was confirmed with cDNA derived from a fibroblast line from subject IV-6. PCR amplification and sequencing by a forward primer in exon 4 and a reverse primer in exon 3 in the subject's cDNA resulted in a PCR product of the predicted length and sequence, confirming that exon 5 was followed by exon 3 and thus proving the forward orientation of the duplication ( Figure 2C ). This duplication also results in a c.686_687delinsAT (p.Arg229Asn) (NM_001024630.3) change at the breakpoint between exon 5 and exon 3. On the protein level, the duplication of exons 3 to 5 of RUNX2 thus leads to a p.[Pro21_Arg229dup; Arg229Asn] change. Residue 229 of RUNX2 is an evolutionary conserved amino acid ( Figure S2) .
The functional consequences of the duplication in exons 3 to 5 of RUNX2 were assessed by introducing a similar duplication in murine Runx2 cDNA. The construct led to the duplication of amino acids 25 to 232 of murine RUNX2 (corresponding to residues 25 to 225 in human RUNX2) and included the Q/A and runt domains, with the exception of the last four amino acids of the runt domain ( Figure S2 ). Equal amounts of expression plasmids containing mutated and wild-type Runx2 cDNA were transfected into HEK293 cells. The resulting intracellular RUNX2 proteins migrated at their predicted molecular masses of 57 kDa and 80 kDa, respectively ( Figure 3A) . Protein levels were markedly higher for the mutated RUNX2 than for wild-type RUNX2. In addition, we compared the transactivation activity of the mutant to that of the wild-type RUNX2, using a reporter construct based on the mouse osteocalcin promoter, which has been well characterized as an osteoblast-specific target of RUNX2. 8 Cotransfection of equal amounts of these constructs in HEK293 cells demonstrated increased transactivation activity for the mutated RUNX2 ( Figure 3B) . A separate analysis of the functional effect of the isolated Arg to Asn change at the breakpoint residue 229 showed that this sequence change led to decreased transactivation activity ( Figure 3B ). Overall, these transfection experiments suggested that the duplication of exons 3 to 5 leads to some loss of transactivation activity of the RUNX2 protein as a result of the amino acid change at residue 229, but a marked increase in intracellular RUNX2 protein levels, with the composite effect of a gain in function.
Mice overexpressing Runx2 in osteoblasts have an abnormally low number of osteocytes in cortical bone. 9, 10 We therefore determined cortical osteocyte density in the iliac bone samples from subjects IV-1, IV-2, and IV-6 and in three age-matched control samples that were taken from our reference collection. 11 This revealed that osteocyte density (the number of osteocytes relative to the cortical bone area of the section) was 32% lower in the samples from affected individuals than in controls (mean 5 SE: 186 5 13 mm À2 versus 272 5 4 mm À2 ).
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p.Arg236Asn Figure 3 . Functional Characterization of the Intragenic RUNX2 Duplication (A) Immunoblot analysis of mouse RUNX2 proteins (mRUNX2) overexpressed in HEK293 cells. Cells were transfected with equal amounts of expression plasmids encoding green fluorescent protein (GFP), wild-type mouse RUNX2 (wt mRUNX2), or mutant mouse RUNX2 (mut mRUNX2) carrying a duplication of exons 3 to 5. At the indicated time points after transfection, total cellular extracts were prepared and analyzed by immunoblotting. The asterisk points to an undetermined minor immunoreactive protein that appears only in lanes containing mutant mRUNX2. The blot was rehybridized for actin as a loading control. RUNX2 protein levels are much higher for the mutated than for the wild-type protein at all three time points. (B) Relative activity of the mouse À1.1 kb osteocalcin promoter-luciferase reporter construct 42 hr after cotransfection with 300 ng of plasmids encoding the wildtype mouse RUNX2, the mutant mouse RUNX2, or the wild-type mouse RUNX2 harboring a missense mutation (p.Arg236Asn, corresponding to a p.Arg229Asn change in human RUNX2). Data represent means 5 SD from three independent experiments and are expressed as fold induction relative to the GFP control. The duplication in RUNX2 leads to higher transactivation activity, whereas the p.Arg236Asn mutation is associated with lower transactivation activity. (C) Backscattered electron image of iliac bone sample from subject IV-1. (D) Results of bone mineralization density distribution analysis in trabecular bone from subjects IV-1, IV-2, and IV-6, compared to age-matched reference data in cancellous bone (Cn-Young). 22 In all three samples the distribution curve is shifted toward higher mineralization density compared to control values.
Runx2 transgenic mice have a lower-than-normal average material density of trabecular bone. 10 Therefore, material bone density was also determined in the iliac bone samples from subjects IV-1, IV-2, and IV-6, but in contrast to the mouse studies we found that material density was slightly increased compared to controls ( Figure 3C ). In this report we present a kindred in which several members presented with the MDMHB phenotype. Even though the family link to the MDMHB kindred described by Halal et al. 1 could not be ascertained, the family presented here had strikingly similar features and originated from the same geographic area. The main phenotypic difference between the two families is that Halal et al. 1 had reported brachydactyly, whereas acral abnormalities were not observed in the individuals presented here. However, brachydactyly was an inconsistent feature in the family described by Halal et al. 1 Therefore, we consider it very likely that the family described by Halal et al. 1 and the individuals presented here have in fact the same disorder, MDMHB, and may in fact be individuals from the same extended family. RUNX2 is the master regulator of both osteoblast and terminal chondrocyte differentiation and is essential for in vivo bone formation and mineralization. 4, 12 A large number of bone-related genes are regulated by RUNX2, which binds to DNA and heterodimerizes with the transcriptional coactivator core binding factor b. 13 Both of these functions are mediated by the runt domain that is duplicated in individuals with MDMHB.
14 Until now, CCD has been the only disorder associated with RUNX2 mutations. All of the more than 170 RUNX2 mutations reported until now are believed to result in loss of RUNX2 function and lead to CCD. [6] [7] [8] 15 MDMHB affects similar skeletal sites as CCD, but in some ways represents the mirror image of CCD. Clavicles are enlarged in MDMHB but are hypoplastic or absent in CCD. In MDMHB, the cranial vault is thickened whereas there is a lack of skull mineralization in CCD. Persons with MDMHB present with dystrophic teeth, whereas CCD is associated with supernumerary teeth. The MDMHB phenotype is also different from that caused by duplications of the entire RUNX2 locus, which are associated with susceptibility to premature cranial suture fusion. 16, 17 The clinical findings of MDMHB and the results of our mechanistic studies are in accordance with the notion that the duplication of exons 3 to 5 leads to a gain of function in RUNX2. This gain of function may result from increased cellular levels of mutated RUNX2 protein, as suggested by our transfection experiments. The mechanism leading to this increase in levels of mutated RUNX2 protein was not investigated in this study, but it is known that RUNX2 levels are regulated by complex posttranslational modifications. 18 One or several of these posttranslational modification pathways may be affected by the duplication. The situation is made even more complicated by the fact that the duplication of exons 3 to 5 in RUNX2 not only leads to the addition of 209 amino acids to the protein but also introduces an amino acid change at the breakpoint residue 229, which by itself seems to lead to a decrease in transactivation activity of RUNX2. Possibly, the marked increase in the amount of mutated protein overrides this decrease in function. RUNX2 is an important regulator of osteoblast function, so it may be surprising that the in vivo consequence of this putative gain-of-function mutation was decreased osteoblast activity, as shown by the low mineral apposition rate in bone samples of subjects with MDMHB. A similar discrepancy between in vitro and in vivo effects was found in Runx2-overexpressing mice. 19 A possible explanation is that RUNX2 must be suppressed during osteoblast differentiation for immature osteoblasts to become fully mature. 9, 10, 20 A gain of RUNX2 function may therefore interfere with osteoblast maturation, which is consistent with our observation that in bone tissue of individuals with MDMHB there are fewer-than-normal osteocytes, the terminal stage of osteoblast maturation. Correspondingly, mice overexpressing Runx2 in osteoblasts have a severe deficit in bone formation, leading to thin long-bone cortices, low bone mass, and low osteocyte density. 9, 10 Similarly, overexpression of Runx2 in odontoblasts interferes with the maturation of these cells and leads to disordered tooth structure. 21 These skeletal and dental features of Runx2 overexpression in mice were also present in individuals with MDMHB. However, it appears that bones arising through intramembranous bone formation (skull, clavicle) do not follow the same pattern; indeed, the radiographic appearance of clavicles and skull suggests that the amount of bone is increased at these locations. The effect of Runx2 overexpression on bone resorption is somewhat inconsistent between mouse models; both normal and markedly elevated bone resorption have been reported. 9, 10 In subjects with MDMHB, there was no indication of increased bone resorption and bone turnover seemed to be somewhat low. This is consistent with the finding that material bone density was slightly elevated in the bone samples from these individuals. Lower bone turnover means that the average time since bone deposition at a given skeletal location is higher, allowing more time to complete bone matrix mineralization. In summary, this report shows that MDMHD is caused by a duplication in RUNX2 that may lead to a gain-offunction and a bone formation defect, thus enlarging the phenotypic spectrum associated with dysregulation of RUNX2 function.
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